{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:40:44Z","timestamp":1773124844063,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010607","name":"Universit\u00e0 degli Studi di Perugia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010607","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>COVID-19 vaccines have been recommended to people with multiple sclerosis (pwMS) and, to ensure durable immunity, a third booster dose has been administered in several countries. Data about potential risks associated with the third booster dose in pwMS, such as vaccine-triggered disease exacerbations, are still scarce.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To investigate whether the administration of a third booster dose of mRNA COVID-19 vaccines was associated with an increased risk of short-term disease reactivation in a large cohort of pwMS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively selected 1265 pwMS who received a third booster dose of an mRNA COVID-19 vaccine. Demographic and clinical data were collected, including the presence, number and characteristics of relapses in the 60\u00a0days prior to and after the third booster dose.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the selected cohort, the relapse rate in the two months after administration of the third booster dose of mRNA COVID-19 vaccines did not increase when compared with the prior two months. Indeed, the percentage of pwMS experiencing relapses in the 60\u00a0days following the administration of the third booster dose was 2.1%, similar to the percentage recorded in 60\u00a0days prior to vaccination, which was 1.9%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The third booster dose of mRNA COVID-19 vaccines appeared to be safe for pwMS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-023-12034-0","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T07:02:11Z","timestamp":1698994931000},"page":"24-31","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose"],"prefix":"10.1007","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2645-7477","authenticated-orcid":false,"given":"Massimiliano","family":"Di Filippo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Ragonese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Prosperini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia Teresa","family":"Maniscalco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Cavalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Lorefice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Nociti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Di Sabatino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marinella","family":"Clerico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Guaschino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Radaelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Fantozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Buttari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Laroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Gajofatto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Malucchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damiano","family":"Paolicelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Tomassini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Lanzillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Moccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Solaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Cocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Gasperini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Tortorella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the RIREMS (Rising Researchers in MS) group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,3]]},"reference":[{"issue":"4","key":"12034_CR1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.bj.2020.05.021","volume":"43","author":"HI Shih","year":"2020","unstructured":"Shih HI, Wu CJ, Tu YF, Chi CY (2020) Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines. Biomed J 43(4):341\u2013354. https:\/\/doi.org\/10.1016\/j.bj.2020.05.021. (PMID: 32532623)","journal-title":"Biomed J"},{"issue":"9","key":"12034_CR2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.149187","volume":"6","author":"JL Golob","year":"2021","unstructured":"Golob JL, Lugogo N, Lauring AS, Lok AS (2021) SARS-CoV-2 vaccines: a triumph of science and collaboration. JCI Insight 6(9):e149187. https:\/\/doi.org\/10.1172\/jci.insight.149187. (PMID: 33822773)","journal-title":"JCI Insight"},{"key":"12034_CR3","doi-asserted-by":"publisher","unstructured":"Polack FP, Thomas SJ, Kitchin N, et al. C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603\u20132615. doi: https:\/\/doi.org\/10.1056\/NEJMoa2034577. PMID: 33301246.","DOI":"10.1056\/NEJMoa2034577"},{"key":"12034_CR4","doi-asserted-by":"publisher","unstructured":"Baden LR, El Sahly HM, Essink B, et al; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384 (5):403\u2013416. doi: https:\/\/doi.org\/10.1056\/NEJMoa2035389. PMID: 33378609.","DOI":"10.1056\/NEJMoa2035389"},{"issue":"3","key":"12034_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.autrev.2013.10.003","volume":"13","author":"D Karussis","year":"2014","unstructured":"Karussis D, Petrou P (2014) The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev 13(3):215\u2013224. https:\/\/doi.org\/10.1016\/j.autrev.2013.10.003. (PMID: 24514081)","journal-title":"Autoimmun Rev"},{"key":"12034_CR6","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.3389\/fimmu.2019.01883","volume":"10","author":"T Zrzavy","year":"2019","unstructured":"Zrzavy T, Kollaritsch H, Rommer PS et al (2019) Vaccination in multiple sclerosis: friend or foe? Front Immunol 10:1883. https:\/\/doi.org\/10.3389\/fimmu.2019.01883. (PMID: 31440255)","journal-title":"Front Immunol"},{"key":"12034_CR7","doi-asserted-by":"publisher","unstructured":"Rakusa M, \u00d6zt\u00fcrk S, Moro E, et al (2022) European Academy of\u00a0Neurology NeuroCOVID-19 Task\u00a0Force. COVID-19 vaccination hesitancy among people with chronic neurological disorders: A position paper. Eur J Neurol 29 (8): 2163\u20132172. doi: https:\/\/doi.org\/10.1111\/ene.15368. PMID: 35460319.","DOI":"10.1111\/ene.15368"},{"issue":"7","key":"12034_CR8","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3390\/vaccines9070773","volume":"9","author":"V Cabreira","year":"2021","unstructured":"Cabreira V, Abreu P, Soares-Dos-Reis R et al (2021) Multiple sclerosis, disease-modifying therapies and COVID-19: a systematic review on immune response and vaccination recommendations. Vaccines (Basel) 9(7):773. https:\/\/doi.org\/10.3390\/vaccines9070773. (PMID: 34358189)","journal-title":"Vaccines (Basel)"},{"issue":"6","key":"12034_CR9","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1177\/13524585211003476","volume":"27","author":"A Achiron","year":"2021","unstructured":"Achiron A, Dolev M, Menascu S et al (2021) COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by february 2021. Mult Scler 27(6):864\u2013870. https:\/\/doi.org\/10.1177\/13524585211003476. (PMID: 33856242)","journal-title":"Mult Scler"},{"issue":"11","key":"12034_CR10","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1111\/ene.15028","volume":"28","author":"I Lotan","year":"2021","unstructured":"Lotan I, Wilf-Yarkoni A, Friedman Y et al (2021) Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel. Eur J Neurol 28(11):3742\u20133748. https:\/\/doi.org\/10.1111\/ene.15028. (PMID: 34288285)","journal-title":"Eur J Neurol"},{"key":"12034_CR11","doi-asserted-by":"publisher","unstructured":"Di Filippo M, Cordioli C, Malucchi S, et al (2022) RIREMS (Rising Researchers in MS) group. mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. J Neurol Neurosurg Psychiatry 93 (4): 448\u2013450. doi: https:\/\/doi.org\/10.1136\/jnnp-2021-327200. PMID: 34408003.","DOI":"10.1136\/jnnp-2021-327200"},{"key":"12034_CR12","doi-asserted-by":"publisher","unstructured":"Epstein S, Xia Z, Lee AJ, et al. (2022) Multiple Sclerosis Resilience to COVID-19 (MSReCOV) Collaborative Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety\/Tolerability Data. Mult Scler Relat Disord 57: 103433. Doi: https:\/\/doi.org\/10.1016\/j.msard.2021.103433. PMID: 34923427.","DOI":"10.1016\/j.msard.2021.103433"},{"key":"12034_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103690","volume":"59","author":"E Ciampi","year":"2022","unstructured":"Ciampi E, Uribe-San-Martin R, Soler B et al (2022) Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with multiple sclerosis. Mult Scler Relat Disord 59:103690. https:\/\/doi.org\/10.1016\/j.msard.2022.103690. (PMID: 35182880)","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"12034_CR14","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3390\/vaccines10050763","volume":"10","author":"A Czarnowska","year":"2022","unstructured":"Czarnowska A, Tarasiuk J, Zajkowska O et al (2022) Safety of Vaccines against SARS-CoV-2 among polish patients with multiple sclerosis treated with disease-modifying therapies. Vaccines (Basel) 10(5):763. https:\/\/doi.org\/10.3390\/vaccines10050763. (PMID: 35632519)","journal-title":"Vaccines (Basel)"},{"key":"12034_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104167","volume":"68","author":"L Kong","year":"2022","unstructured":"Kong L, Wang X, Chen H et al (2022) Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis. Mult Scler Relat Disord 68:104167. https:\/\/doi.org\/10.1016\/j.msard.2022.104167. (PMID: 36170773)","journal-title":"Mult Scler Relat Disord"},{"key":"12034_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.721502","volume":"12","author":"GT Maniscalco","year":"2021","unstructured":"Maniscalco GT, Manzo V, Di Battista ME et al (2021) Severe multiple sclerosis relapse after COVID-19 vaccination: a case report. Front Neurol 12:721502. https:\/\/doi.org\/10.3389\/fneur.2021.721502. (PMID: 34447349)","journal-title":"Front Neurol"},{"key":"12034_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.765954","volume":"12","author":"R Nistri","year":"2021","unstructured":"Nistri R, Barbuti E, Rinaldi V et al (2021) Case report: multiple sclerosis relapses after vaccination against SARS-CoV2: a series of clinical cases. Front Neurol 12:765954. https:\/\/doi.org\/10.3389\/fneur.2021.765954. (PMID: 34744992)","journal-title":"Front Neurol"},{"key":"12034_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.897275","volume":"13","author":"C Quintanilla-Bord\u00e1s","year":"2022","unstructured":"Quintanilla-Bord\u00e1s C, Gasc\u00f3n-Gimenez F, Alcal\u00e1 C et al (2022) Case report: exacerbation of relapses following mRNA COVID-19 vaccination in multiple sclerosis: a case series. Front Neurol 13:897275. https:\/\/doi.org\/10.3389\/fneur.2022.897275. (PMID: 35572939)","journal-title":"Front Neurol"},{"key":"12034_CR19","doi-asserted-by":"publisher","first-page":"1018785","DOI":"10.3389\/fneur.2022.1018785","volume":"13","author":"V Rinaldi","year":"2022","unstructured":"Rinaldi V, Bellucci G, Buscarinu MC et al (2022) CNS inflammatory demyelinating events after COVID-19 vaccines: a case series and systematic review. Front Neurol 13:1018785. https:\/\/doi.org\/10.3389\/fneur.2022.1018785. (PMID: 36530641)","journal-title":"Front Neurol"},{"issue":"24","key":"12034_CR20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114583","volume":"385","author":"EG Levin","year":"2021","unstructured":"Levin EG, Lustig Y, Cohen C et al (2021) Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 Months. N Engl J Med 385(24):e84. https:\/\/doi.org\/10.1056\/NEJMoa2114583. (PMID: 34614326)","journal-title":"N Engl J Med"},{"key":"12034_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103724","volume":"60","author":"R Capuano","year":"2022","unstructured":"Capuano R, Bisecco A, Conte M et al (2022) Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod. Mult Scler Relat Disord 60:103724. https:\/\/doi.org\/10.1016\/j.msard.2022.103724. (PMID: 35272145)","journal-title":"Mult Scler Relat Disord"},{"issue":"15","key":"12034_CR22","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","volume":"385","author":"YM Bar-On","year":"2021","unstructured":"Bar-On YM, Goldberg Y, Mandel M et al (2021) Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med 385(15):1393\u20131400. https:\/\/doi.org\/10.1056\/NEJMoa2114255. (PMID: 34525275)","journal-title":"N Engl J Med"},{"issue":"7","key":"12034_CR23","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1177\/13524585231167515","volume":"29","author":"R Capuano","year":"2023","unstructured":"Capuano R, Prosperini L, Altieri M et al (2023) Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs. Mult Scler 29(7):856\u2013865. https:\/\/doi.org\/10.1177\/13524585231167515. (PMID: 37165941)","journal-title":"Mult Scler"},{"issue":"3","key":"12034_CR24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1001\/jamaneurol.2021.5109","volume":"79","author":"M K\u00f6nig","year":"2022","unstructured":"K\u00f6nig M, Torgauten HM, Tran TT et al (2022) Immunogenicity and safety of a Third SARS-CoV-2 vaccine dose in patients with multiple sclerosis and weak immune response after COVID-19 Vaccination. JAMA Neurol 79(3):307\u2013309. https:\/\/doi.org\/10.1001\/jamaneurol.2021.5109. (PMID: 35072702)","journal-title":"JAMA Neurol"},{"issue":"12","key":"12034_CR25","doi-asserted-by":"publisher","first-page":"6185","DOI":"10.1007\/s00415-022-11296-4","volume":"269","author":"R Capuano","year":"2022","unstructured":"Capuano R, Altieri M, Conte M et al (2022) Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod. J Neurol 269(12):6185\u20136192. https:\/\/doi.org\/10.1007\/s00415-022-11296-4. (PMID: 35879563)","journal-title":"J Neurol"},{"key":"12034_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120155","volume":"434","author":"S Dreyer-Alster","year":"2022","unstructured":"Dreyer-Alster S, Menascu S, Mandel M et al (2022) COVID-19 vaccination in patients with multiple sclerosis: safety and humoral efficacy of the third booster dose. J Neurol Sci 434:120155. https:\/\/doi.org\/10.1016\/j.jns.2022.120155. (PMID: 35091386)","journal-title":"J Neurol Sci"},{"issue":"2","key":"12034_CR27","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2. (PMID: 29275977)","journal-title":"Lancet Neurol"},{"key":"12034_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103163","volume":"54","author":"DM Ehde","year":"2021","unstructured":"Ehde DM, Roberts MK, Humbert AT et al (2021) COVID-19 vaccine hesitancy in adults with multiple sclerosis in the United States: a follow up survey during the initial vaccine rollout in 2021. Mult Scler Relat Disord 54:103163. https:\/\/doi.org\/10.1016\/j.msard.2021.103163. (PMID: 34325399)","journal-title":"Mult Scler Relat Disord"},{"key":"12034_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104014","volume":"65","author":"D Stastna","year":"2022","unstructured":"Stastna D, Menkyova I, Drahota J et al (2022) To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection. Mult Scler Relat Disord 65:104014. https:\/\/doi.org\/10.1016\/j.msard.2022.104014. (PMID: 35803085)","journal-title":"Mult Scler Relat Disord"},{"issue":"11","key":"12034_CR30","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.3390\/jcm12113640","volume":"12","author":"N Frahm","year":"2023","unstructured":"Frahm N, Fneish F, Ellenberger D et al (2023) Frequency and predictors of relapses following SARS-CoV-2 vaccination in patients with multiple sclerosis: interim results from a longitudinal observational study. J Clin Med 12(11):3640. https:\/\/doi.org\/10.3390\/jcm12113640. (PMID: 37297838)","journal-title":"J Clin Med"},{"key":"12034_CR31","doi-asserted-by":"publisher","unstructured":"Stefanou MI, Palaiodimou L, Theodorou A, et al. (2023) Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis. Mult Scler. 13524585221150881. doi: https:\/\/doi.org\/10.1177\/13524585221150881. PMID: 36722184.","DOI":"10.1177\/13524585221150881"},{"key":"12034_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104582","volume":"72","author":"A Bertozzi","year":"2023","unstructured":"Bertozzi A, Mariottini A, Marchi L et al (2023) Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: a monocentric experience. Mult Scler Relat Disord 72:104582. https:\/\/doi.org\/10.1016\/j.msard.2023.104582. (PMID: 36889098)","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"12034_CR33","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s00415-011-5984-2","volume":"258","author":"MF Farez","year":"2011","unstructured":"Farez MF, Correale J (2011) Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol 258(7):1197\u20131206. https:\/\/doi.org\/10.1007\/s00415-011-5984-2. (PMID: 21431896)","journal-title":"J Neurol"},{"issue":"Pt 5","key":"12034_CR34","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/brain\/awf098","volume":"125","author":"D Buljevac","year":"2002","unstructured":"Buljevac D, Flach HZ, Hop WC et al (2002) Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125(Pt 5):952\u2013960. https:\/\/doi.org\/10.1093\/brain\/awf098. (PMID: 11960885)","journal-title":"Brain"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-12034-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-12034-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-12034-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T16:18:43Z","timestamp":1704471523000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-12034-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,3]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["12034"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-12034-0","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,3]]},"assertion":[{"value":"7 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MDF participated on advisory boards and steering committees for and received speaker or writing honoraria, research support and funding for travelling from Alexion, BMS, Bayer, Biogen Idec, Genzyme, Horizon, Janssen,\u00a0Merck, Mylan, Novartis, Roche, Siemens Healthineers, Teva and Viatris. DF has received travel grants and\/or fees for speaking and\/or advisory boards from Alexion, Biogen, Bristol-Myers Squibb, Celgene, Merck, Novartis, Roche, Sanofi. PR received grants for speaking or consultancies from: Biogen, Bristoll-Myers-Squibb, Merck, Novartis, Roche, Sanofi Genzyme. GTM received personal compensation from Serono, Biogen, Novartis, Roche and Teva for public speaking and advisory boards. PC received honoraria for consultancy or speaking from Alexion, Biogen, BMS, Merck, Novartis, Sanofi, Roche. LL received honoraria for consultancy or speaking from Biogen, Novartis, Sanofi, Bristol, Merck, Roche. VN has received consulting fees from Novartis, Roche, Mylan, Biogen Idec, Merck, Teva and Bayer; speaker and writing honoraria from Mylan, Teva, Biogen Idec, Bayer, Sanofi Genzyme and Merck and travel grants from Teva, Biogen Idec, Sanofi Genzyme, Roche and Novartis. EDS received travel grants from Sanofi, Biogen, Bristol-Myers Squibb and Novartis to attend national conferences. MaCl received personal compensations for public speaking from Merck, Biogen, Novartis, Sanofi Genzyme, Almirall, Roche and Viatris and received research grants from Merck, Biogen and Novartis. CG has served on scientific advisory boards and received support for travel and congress attendance from Biogen, Novartis, Almirall, Sanofi-Genzyme, Merck-Serono. MR received honoraria or consultation fees from Biogen Idec, Sanofi Genzyme, Novartis and Merck Serono. RF received honoraria or consultation fees from Roche, Novartis, Merck and Sanofi Genzyme. FB received honoraria for consultancy or speaking from Biogen, Bristol, Merck, Roche. AL has received personal compensation from Novartis, Sanofi, Biogen, Merck, Roche, and Bristol-Myers Squibb for public speaking and advisory boards; her research has been funded by Fondazione Italiana Sclerosi Multipla, the Italian Ministry of Health and the Italian Ministry of University. MaCa received honoraria for consultancy or speaking from Biogen, Novartis, Sanofi, BMS, Merck Serono, Roche. SM received honoraria for consultancy or speaking from Biogen, Novartis, Sanofi, Bristol, Merck, Roche. DP received honoraria for consultancy from and\/or speaking at Biogen Idec, Merck-Serono, Almirall, Sanofi-Aventis, Teva, Novartis and Genzyme. GDL served on scientific advisory boards and received speaking honoraria or travel grants from Biogen, Merck Serono, Novartis, Roche and Sanofi Genzyme. VT participated on advisory boards for and received speaker or writing honoraria and funding for traveling from Biogen, Sanofi Genzyme, Merck, Novartis, Roche and Almirall. RL received honoraries from Biogen, Merck, Sanofi, Roche and Novartis for lectures or scientific boards. MM has received research grants from ECTRIMS-MAGNIMS, UK MS Society and Merck; honoraria from EMD Serono, Ipsen, Merck, Roche and Sanofi Genzyme and consultant fees from Veterans Evaluation Services. CS received travel grant and honoraria from Merck, Biogen, Novartis and Amgen. EC has received consulting and\/or lecture fees and\/or travel grants from Biogen Idec, Sanofi Genzyme, Merck Serono, Novartis and Roche. CG received fees for speaking and advisory boards from Merck, Biogen, Novartis, Teva, Roche, Almirall, Bayer, Mylan and Sanofi. CT received honoraria for speaking and travel grants from Biogen, Sanofi Aventis, Merck Serono, Bayer Schering, Teva, Genzyme, Almirall and Novartis. The other authors declare no conflict of interests related to this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}